Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?

Liquidia Corporation LQDA is counting on its lead drug, Yutrepia, to sustain its strong commercial momentum despite intense competition in the pulmonary arterial hypertension (PAH) market.

Yutrepia is an inhaled dry-powder formulation of treprostinil developed using Liquidia’s proprietary PRINT technology. The technology is designed to deliver the drug deeper into the lungs through an easy-to-use inhaler while enabling higher doses than other inhaled treprostinil therapies.

The FDA approved Yutrepia in May 2025 for the treatment of PAH and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Since its commercial launch in June 2025, the drug has quickly emerged as Liquidia’s key growth driver, generating approximately $300.3 million in sales in the first half of 2026. Adoption has also been strong, with about 5,900 unique prescriptions since launch and more than 5,000 patients initiated on Yutrepia. Nearly 1,100 physicians have prescribed the therapy.

Strong Yutrepia sales have helped Liquidia deliver its fourth consecutive profitable quarter, underscoring the drug’s growing commercial traction.

However, sustaining this growth could prove challenging. The PAH market is highly competitive, with numerous established therapies targeting different disease pathways, including endothelin receptor antagonists, phosphodiesterase-5 inhibitors, soluble guanylate cyclase stimulators, activin signaling inhibitors and prostacyclin-based treatments. The availability of both branded and generic options, along with widespread combination use, creates a challenging environment for physician adoption and market share gains.

Liquidia is also seeking to broaden Yutrepia’s growth opportunity. The company plans to evaluate the therapy in pulmonary hypertension associated with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF) and Raynaud’s phenomenon related to systemic sclerosis. Successful expansion into these additional indications could provide Yutrepia with new avenues for long-term growth.

LQDA Faces Competition in PAH Market

Yutrepia competes in the PAH market against several approved inhaled prostacyclin therapies, while additional pipeline candidates could intensify competition in the coming years.

Its primary competitor is United Therapeutics' UTHR Tyvaso (treprostinil), the long-established inhaled therapy approved for PAH in 2009 and PH-ILD in 2021.

United Therapeutics also markets Tyvaso DPI, a dry-powder version of treprostinil approved in 2022 for both indications. Demand for this product has been strong.

United Therapeutics is further expanding its PAH franchise. The company highlighted two major regulatory filings — ralinepag tablets for PAH and nebulized Tyvaso for IPF — as potentially significant catalysts for long-term growth. Additional planned filings for ralinepag DPI and treprostinil SMI could further expand UTHR’s pipeline and growth opportunities.

Insmed INSM is also advancing several clinical-stage programs in respiratory diseases, including TPIP and INS1148.

TPIP is an inhaled dry powder formulation of the treprostinil prodrug treprostinil palmitil, which may offer a differentiated product profile for PH-ILD, PAH, PPF and IPF.The company has made encouraging progress with the program. INSM is currently enrolling patients in the PALM-ILD trial, a phase III study of TPIP in patients with PH-ILD. It is also actively enrolling patients in the PALM-PAH trial, a phase III study of TPIP in those with PAH.

Last month, the company reported positive 12-month data from the ongoing open-label extension study of TPIP in patients with PAH.

The company also plans to initiate a phase III study of TPIP in patients with PPF in the second half of 2026, followed by a phase III study in IPF in the first half of 2027.

Insmed is advancing INS1148 in a phase II program initially focused on PPF and IPF. The company is also exploring additional diseases where inhibiting the inflammatory functions of Stem Cell Factor 248 (SCF248) could provide therapeutic benefits.

Although Yutrepia's proprietary PRINT technology, strong launch trajectory and increasing physician adoption position it well to gain additional market share, its ability to sustain long-term growth will depend on continued execution, successful differentiation from established therapies and expansion of its presence in an increasingly competitive PAH treatment landscape.

LQDA’s Share Price Performance, Valuation & Estimates

Shares of LQDA have surged 96.3% year to date compared with the industry’s growth of  8.9%.

Image Source: Zacks Investment Research

Going by the price/sales ratio, LQDA shares currently trade at 6.16X forward sales, higher than the industry’s average of 1.93X but lower than its mean of 14.68X.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for 2026 earnings per share has moved south to $2.57 from $2.97, and that for 2027 EPS has declined to $4.38 from $4.81 in the past 60 days.

Image Source: Zacks Investment Research

LQDA currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
 

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research